Solarvest BioEnergy Inc.'s Eversea Division Signs Agreement with E3live

Solarvest BioEnergy Inc.'s Eversea Division Signs Agreement with E3live

(TheNewswire)

Solarvest BioEnergy Inc.

Solarvest BioEnergy Inc. ("Solarvest", or the "Company") (TSXV:SVS), ("Solarvest" or the "Company"), is pleased to announce that its wholly-owned division Eversea America Inc. ("Eversea") has signed an agreement with E3Live, one of the organic industry's premier superfood brands. E3Live has agreed to introduce and market Eversea's organic omega-3 DHA products to its customer base

"We get approached all of the time by companies who want us to re-sell their products, and we reject nearly every one of them because they don't meet our very rigorous standards," said Michael Saiber, founder and CEO of E3Live. "I heard about what Eversea was offering and tried it, as I had never come across a USDA certified organic, plant-based omega-3 DHA product. Immediately, my body recognized it as an important and necessary addition to my diet. I believe our customers will be very interested in this product as well. The best testimonial about Eversea's powder that I can give is that I take it every single day."

This initial agreement is for Nanuq TM omega-3 DHA powder, which complements E3Live's A phanizomenon flos-aquae (AFA), a nutrient-dense aqua-botanical (blue-green algae). E3Live has amassed a list of dedicated customers over the last 27 years in the certified organic nutritional algae business.

"Given E3Live's stature in the organic industry when it comes to algae-based superfoods, this partnership is an exciting endorsement for our organic omega-3 DHA product," said Gerri Greenham, CEO of Solarvest. "Both companies are very committed to providing the highest quality algae products in the world, and being able to offer E3Live customers our algae and algae-based products is a perfect fit and ideal opportunity."

About E3Live

Widely regarded as one of the organic industry's premier superfood brands, E3Live has been selling organic health products and aqua-botanicals since 1995. The company's signature superfoods, E3Live and BrainON, are both nutrient-dense aqua-botanical nutritional algae harvested from the pristine waters of Klamath Lake in Oregon.  E3Live employs the highest quality harvesting methods, safety standards, and purity testing, in addition to adhering to strict Good Manufacturing Practices (GMPs) in order to maintain USDA organic certification and Kosher certification.

About Eversea

Eversea has developed the world's first organic omega-3 DHA from algae. It is both USDA and EU certified organic, and it has received Glyphosate Residue Free certification from The Detox Project. The product is also vegan, gluten-free, free from major allergens, and tested for heavy metals and other contaminants. The omega-3 active ingredient in the products is patented and patent-pending

in commercially relevant/important countries globally. The patent has already been issued in Australia, India, and Japan, and the Solarvest patent also covers the production of EPA.

The company's organic algal-based products have natural advantages over fish oil, which is processed from dwindling sea harvests. Eversea's products are based on marine microalgae and their ability to produce high levels of long-chain omega-3 fatty acid oil, primarily docosahexaenoic acid (DHA). Algae production is sustainable, and sustainability is a growing concern for the market.

About Solarvest

Solarvest BioEnergy Inc. is an algae biologics company whose production platform provides an extremely flexible system capable of producing numerous products from omega-3 fatty acids to human therapeutic proteins. The company has successfully demonstrated the expression of high-value therapeutic proteins, viral antigens (immune-stimulating proteins), and Cecropins (antimicrobial peptide/protein). The company has initiated a program for the expression of CBD and THC to be produced in GMP fermentation facilities.

For further information contact:

Gerri Greenham, Chief Executive Officer

Phone: (647) 204-4095

Email: invest@solarvest.ca

Forward-Looking Information

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the terms of the Offering, the completion of the Offering and the expected use of the net proceeds received by the Company. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information, including but not limited to: general business, economic, competitive, geopolitical and social uncertainties; and regulatory risks. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The forward-looking information contained in this news release is expressly qualified in its entirety by this cautionary statement. The Company does not undertake to update any forward-looking information, except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

None of the securities of Solarvest have been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law, and may not be offered or sold in the United States or to, or for the account or benefit of, persons in the United States or "U.S. persons" (as such term is defined in Regulation S under the U.S. Securities Act) absent registration or an exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy in the United States nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

Copyright (c) 2022 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

SVS:CA
The Conversation (0)
Solarvest Bioenergy Inc. Granted Organic Omega-3 Patent in Japan

Solarvest Bioenergy Inc. Granted Organic Omega-3 Patent in Japan

(TheNewswire)

Solarvest BioEnergy Inc.

Solarvest BioEnergy Inc. ("Solarvest", or the "Company") (TSXV:SVS), ("Solarvest" or the "Company"), announces that it has been granted a patent in Japan. The intellectual property protection concentrates on the production of algal biomass, algal cell cultures, lipid compounds, and compositions thereof, including fatty acids, carotenoids, and fat-soluble vitamins. This patent adds additional strength to the Company's existing patent portfolio as it commercializes its line of organic Omega-3 products

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Solarvest To Sell on China's E-Commerce Application Redbook

Solarvest To Sell on China's E-Commerce Application Redbook

(TheNewswire)

Solarvest BioEnergy Inc.

Solarvest ( TSXV:SVS ) is pleased to announce that the Eversea TM "branded" account has been launched on the Chinese e-commerce platform application Redbook

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Solarvest Files Quarterly Financial Statements and MD&A

Solarvest Files Quarterly Financial Statements and MD&A

Solarvest BioEnergy Inc. ("Solarvest" or the "Company") (TSXV: SVS) is pleased to announce that its quarterly statements for the period ended October 31, 2021, related management discussion and analysis have been filed and are now available on www.sedar.com.

For the three months ended October 31, 2021 the Company incurred a net loss of $383,510 compared to a net loss of $1,565,335 for the prior year. At October 31, 2021, the Company had $852,237 (July 31, 2021 - $1,388,244) in cash. Working capital at October 31, 2021 was $212,854 (July 31, 2021 - $587,732). Eversea had increased its inventory and inventory work in process over the last quarter to $29,289 finished goods and $199,156 work in process. This is an increase from the July 31 of $6,155 finished goods and $97,204 work in process.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Solarvest Web Site Launched in Hong Kong to Service South Easy Asia

Solarvest Web Site Launched in Hong Kong to Service South Easy Asia

(TheNewswire)

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Solarvest Files Annual Financial Statements and MD&A

Solarvest Files Annual Financial Statements and MD&A

(TheNewswire)

Solarvest BioEnergy Inc.

TheNewswire - November 19 th 2021 Solarvest BioEnergy Inc. ("Solarvest" or the "Company") (TSXV:SVS) is pleased to announce that its audited financial statements for the year ended July 31, 2021, related management discussion and analysis and associated officer's certifications (collectively, the "Annual Filings") have been filed and are now available on www.sedar.com .

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Genes and chromosomes with "2024" overlay.

Biotech Market Update: Q1 2024 in Review

The first quarter of 2024 witnessed a surge in initial public offerings (IPOs) and mergers and acquisitions (M&A) within the biotech industry, signaling continued interest from investors.

AstraZeneca’s acquisition of start-up Amolyt on March 14, and its longtime biotech partner Fusion Pharmaceuticals for US$2.4 billion on March 19 marked the third acquisition of a radiopharmaceutical developer in recent months. As of writing, there have been 14 M&A deals struck in 2024, according to data from Biopharma Dive.

Investment bank Jefferies released data in early March revealing that the sector was on track to earn its highest quarterly total in three years, reflecting the cautiously optimistic outlook at this year's JPM24 conference.

Keep reading...Show less

AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

Planning Underway for Phase 3 Development of Tezepelumab in COPD

Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE ® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20 from 9:15-11:15 a.m. PDT .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Close up 3D rendering of DNA strands.

Biotech Stocks: 5 Biggest Companies in 2024

What are the top biotech companies? The following five stocks have market capitalizations worth billions of dollars and operate in countries all around the globe.

Plus, these big-name biotech players have pipelines stuffed with potentially disruptive products — and enough revenue to recover should some of those products fail.

This means that investors can experience the excitement of biotech investing while minimizing risk. Although returns are never guaranteed, company size can insulate investors from volatility.

Keep reading...Show less
SIRONA BIOCHEM Corporate Update April 2024

SIRONA BIOCHEM Corporate Update April 2024

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") provides the following update:

Dear shareholders,

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Announces Close of Private Placement

Sirona Biochem Announces Close of Private Placement

Vancouver, British Columbia – April 4, 2024 Sirona Biochem Corp . (TSX-V: SBM) (Frankfurt: ZSB) (" Sirona ") has closed its private placement (Private Placement") for gross proceeds of $132,500 CAD. The Private Placement consists of 1,325,000 units, (the "Units") at a price of $0.10 per Unit. Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of issue at a price of $0.15 per Share in year one and $0.25 per Share in year two. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Need injecting into red and white cell.

How to Invest in Biotechnology (Updated 2024)

Investors interested in the life science sector are well aware of the importance of biotechnology.

From finding cures for diseases to feeding future generations, many areas of day-to-day life are influenced by players in the biotechnology space, and expert projections show the industry's future looks bright.

But how can investors gain exposure to biotechnology? Here’s a brief overview of how to invest in the expanding biotechnology market, from stocks to watch to exchange-traded funds (ETFs).

Keep reading...Show less

Latest Press Releases

Related News

×